md-medicaldata

Authors

 

Danijela Đurić-Petković¹ , Elizabeta Ristanović<sup>1

1</sup>Vojnomedicinska akademija, Institut za mikrobiologiju, Beograd

 

UDK: 616.45-089-06(497.11)"2012/2016"

The paper was received / Rad primljen: 17.06.2020.

Accepted / Rad prihvaćen: 22.06.2020.

 

Correspondence to:

Danijela Đurić Petković
Vojnomedicinska akademija
Institut za mikrobiologiju
Crnotravska 17
Beograd
telefon 063 440-482
e-mail: danijeladjuricpetkovic@gmail.com

 

 

Sažetak

 

Citomegalovirus (CMV) je uzročnik brojnih komplikacija nakon transplantacije matičnih ćelija hematopoeze (TMĆH) kao što su pneumonija, retinitis, gastroenteritis, hepatitis, infekcije CNS. CMV je  jedan od najznačajnijih faktora  mortaliteta i morbiditeta nakon transplantacije matičnih ćelija. Za praćenje naših pacijenata koristili smo CMV DNK kvantitativni Real-time test lančane reakcije polimeraze. Naš cilj je bio utvrđivanje  viremije CMV kod pacijenata nakon TMĆH.                                     

 

 

 

Ključne reči:

Citomegalovirus, alogena transplantacija, viremija.

 

 

Abstract

 

Background/Aim. Cytomegalovirus (CMV) causes major complications after allogeneic stem cell transplantation (SCT) such as pneumonia, retinitis, gastroenteritis, hepatitis, CNS infections. CMV is still a major cause of morbidity and mortality after hematopoietic cell transplantation. For CMV DNA monitoring in the samples of our patients we used quantitative real-time polymerase chain reaction (PCR) assays. The aim was use to determine CMV loads in patients undergoing SCT. Methods: A total of 50 SCT patients were studied during a 100 days period after transplantation for the presence of CMV DNA. Polymerase chain reaction (PCR) CMV DNA was performed on 488 full blood samples using Gene Proof CMV DNA tests. Results: CMV viremia was detected in 27/50 (54%) of the patients. The median posttransplantation time for the first positive PCR result was 35,15 days after SCT. Detected viral CMV load was between 336 copies/ml and 27800 copies/ml. Conclusion. Early detection of CMV in blood is very important for preemptive therapy. It is better to prevent than to treat CMV disease and its possible consequences.

 

 

Key words:

Cytomegalovirus, allogeneic transplantation, viral load.

 

 

References:

1. Minton K. Viral immunity: How CMV bypasses immune memory. Nat Rev Immunol 2010; 10: 288.
2. Gratwohl, A., Brand, R., Frassoni, F., Rocha, V., Niederwieser, D., Reusser, P., et al. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant. 36 ; 2005. 757–769. doi: 10.1038/sj.bmt.1705140.
3. Ozdemir E., Saliba R.M., Champlin R.E., Couriel D.R., Giralt S.A., DeLima M, Khouri .IF., Hosing C., Kornblau S.M., Anderlini P., Shpall.E.J., Qazilbash M.H., Molldrem J.J., Chemaly R.F., Komanduri K.V. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematologicalmalignancies. Bone Marrow Transplant 2007; 40: 125-136.  
4. Luo X.H., Chang Y.J., Huang X.J. Improving cytomegalovirusspecific T cell reconstitution after haploidentical stem cell transplantation. J Immunol Res 2014; 2014: 631951.
5. Meyers J.D., Ljungman P., Fisher L.D. Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: importance of cytomegalovirus viremia. J Infect Dis, 1990;162: 373–80.
6. Meijer E., Boland G.J., Verdonck L.F. Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants. Clin Microbiol Rev 2003; 16: 647–57.
7. Reusser P., Einsele H., Lee J., Volin L., Rovira M., Engelhard D., et al. Randomised multicenter trial of foscarnet versus ganciclovir for pre-emptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002; 99: 1159–64.
8. Broers, A. E., van Der Holt, R., van Esser, J. W., Gratama, J. W., Henzen-Logmans, S., Kuenen-Boumeester, V., et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood 95,2000; 2240–2245.
9. Zhu  D., Pan  C., Sheng  J., Liang, H., Bian  Z., Liu  Y., et al. Human cytomegalovirus reprogrammes haematopoietic progenitor cells into immunosuppressive monocytes to achieve latency. Nat. Microbiol. 3, 2018; 503–513. doi:10.1038/s41564-018-0131-9.
10. Reeves  M. B., Lehner  P. J., Sissons  J. G., Sinclair J.H. An in vitro model for the regulation of human cytomegalovirus latency and reactivation in dendritic cells by chromatin remodelling. J. Gen. Virol. 86 (Pt 11), 2005a; 2949–2954. doi:10.1099/vir.0.81161-0.
11. Forte  E., Swaminathan  S., Schroeder  M. W., Kim  J. Y., Terhune  S. S. and Hummel M. Tumor necrosis factor alpha induces reactivation of human cytomegalovirus independently of myeloid cell differentiation following posttranscriptional establishment of latency. MBio 9, 2018; e01560-18. doi: 10.1128/ mBio.01560-18.
12. Takenaka K., Nishida  T., Asano-Mori  Y., Oshima  K., Ohashi K., Mori T. et al. Cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation is associated with a reduced risk of relapse in patients with acute myeloid leukemia who survived to day 100 after transplantation. Biol. Blood Marrow Transplant. 21, 2015; 2008-2016. doi:10.1016/j.bbmt.2015.07.019.
13. De la Camara R. CMV in hematopoeitic Stem Cell transplantation. Mediterr J Hematol Infect Dis 2016; 8(1): e2016031, doi: 10.4084/MJHID.2016.031.
14. Cannon, M. J., Schmid, D. S., and Hyde, T. B. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev. Med. Virol. 20,2010; 202–213. doi: 10.1002/rmv.655.
15. George, B., Pati, N., Gilroy, N., Ratnamohan, M., Huang, G., Kerridge, I., et al.Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy. Transpl. Infect. Dis. 12, 2010; 322–329. doi: 10.1111/j.1399-3062.2010.00504.x.
16. Kuljić-Kapulica N., Stamatović D., Savić D., Jovanović D., Tukić Lj., Anđelković N. Praćenje infekcije citomegalovirusom posle alogene transplantacije matičnih ćelija hematopoeze. Vojnosanitetski pregled 2010, vol. 67, br. 5, str. 375-378.
    
    

PDF Đurić Petković D. and Ristanović E. • MD-Medical Data 2020;12(2): 087-089